The U.S. Food and Drug Administration today approved the Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients.
Similar Posts
ZapMax may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use ZapMax, a product promoted and sold for sexual enhancement on various websites, including www.amazon.com, and possibly in some retail stores.Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Drug Shortage Mitigation Efforts
The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law on March 27, 2020 to aid response efforts and ease the economic impact of COVID-19.Ashfiat Alharamain Energy Support may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Ashfiat Alharamain Energy Support, a product promoted and sold for male sexual enhancement on various websites, including Amazon.com (Akkarco, LLC storefront), and possibly in some retail stores.Zen Enterprises LLC – 678407 – 09/11/2024
Failure to Register and ListTraining Course: Achieving Data Quality and Integrity in Maximum Containment Laboratories
To help address challenges associated with ensuring data quality and integrity in regulated studies conducted in BSL-4 laboratories to support MCM development, FDA and UTMB collaborate to provide an annual training course on how to meet GLP requirements in BSL-4 facilitiesAccupack Midwest, Inc. – 680228 – 08/15/2024
CGMP/Finished Pharmaceuticals/Adulterated